| 5.81 0.64 (12.38%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.58 | 1-year : | 8.85 |
| Resists | First : | 6.48 | Second : | 7.58 |
| Pivot price | 3.8 |
|||
| Supports | First : | 4.21 | Second : | 2.8 |
| MAs | MA(5) : | 4.33 |
MA(20) : | 3.71 |
| MA(100) : | 2.53 |
MA(250) : | 1.9 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 67.1 |
D(3) : | 57.8 |
| RSI | RSI(14): 83.6 |
|||
| 52-week | High : | 6.48 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ERAS ] has closed above the upper band by 24.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 362.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.37 - 6.4 | 6.4 - 6.42 |
| Low: | 4.3 - 4.32 | 4.32 - 4.33 |
| Close: | 5.77 - 5.81 | 5.81 - 5.86 |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Thu, 08 Jan 2026
What's Going With Cancer Biotech Erasca Stock On Thursday? - Benzinga
Wed, 07 Jan 2026
What's Happening With Cancer Biotech Erasca Shares This Thursday? - Bitget
Wed, 07 Jan 2026
Erasca stock pulls back after 25% jump, Stifel cites competitor data - Investing.com
Sun, 21 Dec 2025
Erasca, Inc.(NasdaqGS: ERAS) added to S&P Biotechnology Select Industry Index - MarketScreener
Mon, 15 Dec 2025
Erasca Inc stock hits 52-week high at $3.68 - Investing.com
Tue, 09 Dec 2025
Mizuho Maintains Erasca (ERAS) Outperform Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 284 (M) |
| Shares Float | 167 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 81 (%) |
| Shares Short | 16,960 (K) |
| Shares Short P.Month | 16,250 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.8 % |
| Return on Equity (ttm) | -32 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -98 (M) |
| Levered Free Cash Flow | -67 (M) |
| PE Ratio | -13.52 |
| PEG Ratio | 0 |
| Price to Book value | 4.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|